Previous studies have documented the roles of transport via the reduced folate carrier, retention via polyglutamylation and increased levels of the target enzyme, dihydrofolate reductase in sensitivity to methotrexate. Recent studies have shown that the mitochondrial enzymes in the cellular metabolism of serine, folate and glycine are overexpressed in a subset of human cancers and that their expression is required for tumor maintenance. In this Perspective, we propose that expression of mitochondrial enzymes in the metabolism of serine and glycine, in addition to those involved in folate metabolism, are determinants of the response to methotrexate. Further we show that Myc activation in tumors is associated with up regulation of these enzymes. We propose that patients whose tumors that show this phenotype will be sensitive to folate antagonists targeting thymidylate or purine biosynthesis.
Introduction
Previous studies have documented the roles of transport via the reduced folate carrier (RFC), retention via polyglutamylation and increased levels of the target enzyme, dihydrofolate reductase in sensitivity to the folate antagonists methotrexate (MTX) pralatrexate and pemetrexate (1) . Although these factors explain in part why tumor cells are sensitive or resistant to antifolates, they do not fully account for selectivity. Two recent publications have now provided insight for why some tumor cells, as compared to normal replicating cells, are sensitive to MTX: cancer cells that undergo metabolic reprogramming and are characterized by rapid proliferation and up regulate glycine consumption and metabolism are potently inhibited by MTX while normal cells with similar proliferative rates are not as sensitive.
The contribution by Jain et al (2) showed that metabolic reprogramming that occurs in cancer may lead to higher expression of the mitochondrial glycine biosynthetic pathway and up regulation of mitochondrial folate enzymes that include serine hydroxymethyl transferase (SHMT2), methylenetetrahydrofolate dehydrogenase (MTHFD2) and tetrahydrofolate synthetase (MTHFD1L) (see Fig1). The up regulation of these mitochondrial enzymes correlated with increased proliferation, while the folate cytosolic enzymes were not up regulated. Unlike the trifunctional cytosolic enzyme, MTHFD1, that contains methylenetetrahydrofolate dehydrogenase, methenyltetrahydrofolate cyclohydrolase and formyltetrahydrofolate synthetase activity, the mitochondrial enzyme MTHFD2 is a bifunctional enzyme that contains methylenetetrahydrofolate dehydrogenase and methenyltetrahydrofolate cyclohydrolase activity.
Formyltetrahydrofolate synthetase activity is encoded by a separate enzyme, MTHFD1L.
Research. These enzymes contribute to the synthesis and utilization of glycine, methylene THF, and N-10 formyl THF for de novo purine and thymidylate biosynthesis (Fig. 1) .
Supporting the importance of the above pathway is the high expression of mitochondrial 1-carbon pathway components in embryos. A developmental period marked by high cell proliferation rates, embryogenesis requires significant amounts of protein, lipid and nucleic acid synthesis, of similar nature to neoplastic cells. MTHFD1L was found to be up regulated in mouse embryos, with the mitochondria providing greater than 75% of the 1-carbon units present in the cytoplasm used for purine synthesis and other biosynthetic pathways (3). MTHDF1L and MTHFD2 are targets of microRNA miR-9, which may act as a tumor suppressor in regard to these and other genes (4) . High expression of miR-9 suppresses levels of MTHFD1L and MTHFD2 and miR-9 has been found to be down regulated in breast cancer cell lines (4) . Increasing miR-9 levels or knocking down MTHFD2 and MTHFD1L enzyme levels were not assessed, and emphasis was focused on the role of glycine decarboxylase to generate methylenetetrahydrofolate, the onecarbon donor for thymidylate biosynthesis. As the glycine decarboxylase enzyme complex is also located in mitochondria of mammalian cells (7), this further demonstrates the role of the mitochondria in proliferation by supplying tumor cells with precursors for pyrimidine biosynthesis. In this regard, an earlier report showed that transformation imposes a stress on cancer cells in that the demand for nucleotide formation is difficult for the cell to meet (8) . As suggested by both Jai et al and Zhang et al, inhibitors of glycine decarboxylase and or serine hydroxymethyl transferase may be novel targets for tumors in which proliferation is driven by over expression of these enzymes.
Sensitivity to methotrexate in vitro and in vivo
Here, we provide evidence to show that known potent and clinically approved inhibitors (Fig. 2a) , including the genes coding for the folate mitochondrial enzymes SHMT2 (p-value=3.8×10 -4 ) and GLDC (p-value=5.4×10 -3 ), as well as SLC19A1 (coding for the RFC, p-value=4.1×10
) and PHGDH (pvalue=1.5×10 -2 ). These data support the hypothesis that MTX and potentially other inhibitors of thymidylate and purine biosynthesis could be used to target cancers with high rates of proliferation.
To provide further evidence we analyzed a study reporting the response of acute lymphoblastic leukemia (ALL) patients to MTX treatment (11). This study reports the leukemia cell counts before and after treatment together with the leukemia gene expression profiles before treatment. We used the fold change reduction in leukemia cell count as a quantification of sensitivity to MTX treatment. A strong correlation was observed between the sensitivity to MTX treatment and increased expression of the genes coding for the folate mitochondrial enzymes SHMT2 (p-value=1.6×10 -2 ) and MTHFD2
) as well as the gene SLC19A1 (p-value=1.1×10 -2 ) coding for the RFC (Fig. 2b) . Surprisingly, the expression of DHFR did not correlate with the response to MTX, underscoring the need to include the folate mitochondrial enzymes in the investigation of the mechanisms of response to MTX.
What malignancies may be expected to be sensitive to methotrexate ?
Research. 
Another key aspect is to have an estimate of the patient population size that could be targeted using this approach. To this end, we used as a proxy a set of genes coding for We hypothesize that cancers overexpressing a subset of these genes are more dependent on folate metabolism and, therefore, could benefit from treatment with MTX. However, we note that this signature is not a predictor of sensitivity to MTX, but rather a rough quantification of the potential benefit from stratified therapy with MTX. For example, Fig. 2d shows the expression of the folate metabolism genes in a cohort of breast cancer patients. The breast cancer patients can be divided in three groups. On the left we have the subset of cancers with a significant up-regulation (Fig. 2d, Up) of the folate metabolism gene signature, characterized by the concomitant expression of most genes in the gene signature. The color-coded P-value on the right emphasizes in red those genes that tend to be co-expressed. This group of patients is likely to benefit from MTX therapy because their cancers appear to be dependent on folate metabolism. In contrast, the subset of cancers on the right manifest a significant down-regulation of the folate metabolism gene signature (Fig. 2d, Down) Extending this type of analysis to other cancer types, we observe that about 25% of cancers manifest a significant up-regulation of the folate metabolism gene signature and are likely to benefit from treatment with MTX (Table 1 ). There are some variations depending on the cancer subtype, with colorectal cancers and lymphomas reaching slightly more than 30% to the lowest value of about 10% in prostate cancers.
The concomitant expression of genes encoding for enzymes in folate metabolism indicates a common regulatory mechanism. It is known that several serine, folate and glycine metabolism genes are targets of c-Myc (PHGDH, PSPH, SLC19A1, DHFR, (12, 13) , and that their expression is required for cell proliferation. Once again, we used gene signatures as a proxy to quantify the activation of c-Myc targets (12) and cell proliferation (14) . Burkitt's lymphoma is a typical example of a Myc driven cancer (15) . Indeed, from our analysis of a published dataset (16), 88% and 68% of lymphoma classified as Burkitt's lymphoma (BL) and atypical BL, respectively, manifest a significant upregulation of the c-Myc gene signature (Fig. 2c) . Furthermore, as previously noticed (16), there is a group of diffuse large B-cell lymphoma (DLBCL) that is also Myc driven. Indeed, 44% of the DLBCL manifest a significant up-regulation of the c-Myc signature. Focusing on the folate metabolism genes, the P-value column in Fig. 2c highlights in red those genes that are frequently overexpressed (2-fold or higher) in the group of lymphoma with a significant Myc signature up-regulation. In addition to DHFR (p-value=1.5×10 CAN-12-3709 metabolism, c-Myc and proliferation gene signatures is actually a universal feature of human cancers (17). We also note a significant correlation between the up-regulation of the c-Myc and proliferation signatures and the response to MTX in both the in vitro and in vivo studies (Fig. 2a and b, respectively) . More precisely, in the sensitive group there is a significant number of samples manifesting an up-regulation of the c-Myc (in vitro, pvalue=5.1×10 -4 ; in vivo, p-value=2.6×10 -4 ) and proliferation (in vitro, p-value=6.4×10 -6 ; in vivo, p-value=1.5×10 -2 ) signature.
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Conclusions
It will be of importance to learn if known potent and clinically approved inhibitors of thymidylate and purine biosynthesis, that include DHFR inhibitors MTX and pralatrexate and the thymidylate synthase inhibitors 5-fluorouracil and pemetrexed, show selectivity to rapidly proliferating tumors in patients with overexpression of genes coding for mitochondrial folate metabolism enzymes. Based on the concomitant over expression of folate metabolism genes, we estimate that around 25% of patients with cancer manifest this phenotype, and determination of this phenotype will allow patients to be selected for treatment with inhibitors of thymidylate and purine biosynthesis. 
